Irene Luna

Dr. Irene Luna


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in Sensors and Actuators B: Chemical
Verified
Journal Article
Closed access
ADAntonio Doménech-Carbó
Antonio Doménech-Carbó
EVEva Villamón
Eva Villamón
ILIrene Luna
Irene Luna
DRDavid Ramos
David Ramos
CDClara Doménech-Casasús
Clara Doménech-Casasús
CEBRIAN GERARDOCEBRIAN GERARDO
CEBRIAN GERARDO

1 December 2013 in Leukemia Research
Verified
Journal Article
Closed access
ILIrene Luna
Irene Luna
ESEsperanza Such
Esperanza Such
JCJose Cervera
Jose Cervera
EBEva Barragán
Eva Barragán
MIMariam Ibañez
Mariam Ibañez
Miguel SanzMiguel Sanz
Miguel Sanz

2 June 2023 in Cancers
Verified
Journal Article
Open access
PDF file
ÁGÁlvaro Díaz González
Álvaro Díaz González
EMElvira Mora
Elvira Mora
GAGayane Avetisyan
Gayane Avetisyan
SFSantiago Furió
Santiago Furió
RPRosalía De la Puerta
Rosalía De la Puerta
ESEsperanza Such
Esperanza Such
Cytogenetic assessment in myelofibrosis is essential for risk stratification and patient management. However, an informative karyotype is unavailable in a significant proportion of patients. Optical genome mapping (OGM) is a promising technique that allows for a high-resolution assessment of chromosomal aberrations (structural variants, copy number variants, and loss of heterozygosity) in a single workflow. In this study, peripheral blood samples from a series of 21 myelofibrosis patients were analyzed via OGM. We assessed the clinical impact of the application of OGM for disease risk stratification using the DIPSS-plus, GIPSS, and MIPSS70+v2 prognostic scores compared with the standard-of-care approach. OGM, in combination with NGS, allowed for risk classification in all cases, compared to only 52% when conventional techniques were used. Cases with unsuccessful karyotypes (n = 10) using conventional techniques were fully characterized using OGM. In total, 19 additional cryptic aberrations were identified in 9 out of 21 patients (43%). No alterations were found via OGM in 4/21 patients with previously normal karyotypes. OGM upgraded the risk category for three patients with available karyotypes. This is the first study using OGM in myelofibrosis. Our data support that OGM is a valuable tool that can greatly contribute to improve disease risk stratification in myelofibrosis patients.

16 October 2012 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
ILIrene Luna
Irene Luna
ESEsperanza Such
Esperanza Such
JCJose Cervera
Jose Cervera
EBEva Barragán
Eva Barragán
AJAntonio Jiménez-Velasco
Antonio Jiménez-Velasco
Miguel SanzMiguel Sanz
Miguel Sanz

29 July 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
ASANA ISABEL VICENTE SANCHEZ
ANA ISABEL VICENTE SANCHEZ
ILIrene Luna
Irene Luna
JRJuan Carlos Ruiz
Juan Carlos Ruiz
MRMaria José Remigia
Maria José Remigia
AJAndrés Jérez
Andrés Jérez
MSMaría Leonor Senent
María Leonor Senent
The International Consensus Classification of Myeloid Neoplasms and Acute Leukemias (ICC) and the 5th edition of the WHO classification (WHO 2022) have refined the diagnosis of myelodysplastic syndromes (MDS). Both classifications segregate MDS subtypes based on molecular or cytogenetic findings but rely on the subjective assessment of blast cell percentage and dysplasia in hematopoietic cell lineages. This study aimed to evaluate interobserver concordance among 13 cytomorphologists from eight hospitals in assessing blast percentages and dysplastic features in 44 MDS patients. The study found fair interobserver agreement for the PB blast percentage and moderate agreement for the BM blast percentage, with the best concordance in cases with 10% BM blasts. Monocyte count agreement was fair, and dysplasia assessment showed moderate concordance for megakaryocytic lineage but lower concordance for erythroid and granulocytic lineages. Overall, interobserver concordance for MDS subtypes was moderate across all classifications, with slightly better results for WHO 2022. These findings highlight the ongoing need for morphological evaluation in MDS diagnosis despite advances in genetic and molecular techniques. The study supports the blast percentage ranges established by the ICC but suggests refining BM blast cutoffs. Given the moderate interobserver concordance, a unified classification approach for MDS is recommended.

11 April 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
MIMariam Ibáñez
Mariam Ibáñez
ESEsperanza Such
Esperanza Such
ALAlessandro Liquori
Alessandro Liquori
GAGayane Avestisyan
Gayane Avestisyan
RARafael Andreu
Rafael Andreu
ILIrene Luna
Irene Luna
According to current guidelines, in chronic lymphocytic leukemia (CLL), only the TP53 molecular status must be evaluated prior to every treatment’s initiation. However, additional heterogeneous genetic events are known to confer a proliferative advantage to the tumor clone and are associated with progression and treatment failure in CLL patients. Here, we describe the implementation of a comprehensive targeted sequencing solution that is suitable for routine clinical practice and allows for the detection of the most common somatic single-nucleotide and copy number variants in genes relevant to CLL. We demonstrate that this cost-effective strategy achieves variant detection with high accuracy, specificity, and sensitivity. Furthermore, we identify somatic variants and copy number variations in genes with prognostic and/or predictive value, according to the most recent literature, and the tool provides evidence about subclonal events. This next-generation sequencing (NGS) capture-based target assay is an improvement on current approaches in defining molecular prognostic and/or predictive variables in CLL patients.